Octreotide LAR and Prednisone as Neoadjuvant Treatment in Patients with Primary or Locally Recurrent Unresectable Thymic Tumors: A Phase II Study

• Lukas Kirzinger ,

  * E-mail: lukas.kirzinger@medbo.de

  Affiliation Department of Neurology, University of Regensburg, Regensburg, Germany

  ⨯
• Sandra Boy,

  Current address: Asklepios Clinic, Bad Toelz, Germany

  Affiliation Department of Neurology, University of Regensburg, Regensburg, Germany

  ⨯
• Jörg Marienhagen,

  Affiliation Department of Nuclear Medicine, University of Regensburg, Regensburg, Germany

  ⨯
• Gerhard Schuierer,

  Affiliation Institute of Neuroradiology, BKR, Regensburg, Germany

  ⨯
• Reiner Neu,

  Affiliation Department of Thoracic Surgery, University of Regensburg, Regensburg, Germany

  ⨯
• Michael Ried,

  Affiliation Department of Thoracic Surgery, University of Regensburg, Regensburg, Germany

  ⨯
• Hans-Stefan Hofmann,

  Affiliation Department of Thoracic Surgery, University of Regensburg, Regensburg, Germany

  ⨯
• Karsten Wiebe,

  Affiliation Department of Cardiac and Thoracic Surgery, University of Muenster, Muenster, Germany

  ⨯
• Philipp Ströbel,

  Affiliation Institute of Pathology, University of Goettingen, Goettingen, Germany

  ⨯
• Christoph May,

  Affiliation Novartis Pharma GmbH, Nuremberg, Germany

  ⨯
• Julia Kleylein-Sohn,

  Affiliation Novartis Pharma GmbH, Nuremberg, Germany

  ⨯
• Claudia Baierlein,

  Affiliation Novartis Pharma GmbH, Nuremberg, Germany

  ⨯
• Ulrich Bogdahn,

  Affiliation Department of Neurology, University of Regensburg, Regensburg, Germany

  ⨯
• Alexander Marx,

  Affiliation Institute of Pathology, University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany

  ⨯
• Berthold Schalke

  Affiliation Department of Neurology, University of Regensburg, Regensburg, Germany

  ⨯